Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Letter to Congress Regarding the Advancing Access to Precision Medicine Act
-
Group Sign-on Letter to CMS Supporting CY 2019 PFS Changes to Reduce E/M Documentation Burden
-
ACMG Comments to CMS Concerning CLFS Gapfill Preliminary Determinations for GS Codes 81425, 81426, and 81427
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations
-
ACMG Comments to CMS on Proposed NCD for Coverage of NGS for Medicare Beneficiaries with Advanced Cancer (CAG-00450N)
-
Group Sign-on Letter to Congress Supporting the Local Coverage Determination Clarification Act of 2017
-
Joint Comments to CMS Concerning MolDx Program, Medicare Coverage, and Impact on MoPath Gapfill Determinations
-
ACMG Letter to Palmetto GBA Requesting Reconsideration of Cytogenetic Microarray Coverage